5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology

5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology

Exam Focus: Endocrine, renal, and gastrointestinal disorders involve complex hormonal feedback mechanisms, nephron transport dynamics, and epithelial barrier function. Candidates must understand the pathophysiological distinctions between DKA and HHS, the cellular mechanisms of CKD-Mineral and Bone Disorder (CKD-MBD), the differential diagnosis of Acute Kidney Injury (AKI), and the clinical characteristics distinguishing Crohn's disease from ulcerative colitis.

---

Endocrine Pathophysiology

1. Diabetes Mellitus: Type 1 vs Type 2 Pathogenesis

+-------------------------------------------------------------------------+
|                   PATHOPHYSIOLOGY OF DIABETES MELLITUS                  |
+-------------------------------------------------------------------------+
|                                                                         |
|  [TYPE 1 DIABETES]                      [TYPE 2 DIABETES]               |
|  - T-cell autoimmune insulitis          - Peripheral insulin resistance |
|  - Autoantibodies (anti-GAD65, IA-2)    - Hepatic gluconeogenesis excess|
|  - Absolute insulin deficiency          - Relative beta-cell failure    |
|  - Ketosis-prone (DKA)                  - Hyperosmolar-prone (HHS)      |
|  - Onset: Children/young adults         - Onset: Adults, obesity-linked |
|                                                                         |
+-------------------------------------------------------------------------+

• Type 1 Diabetes Mellitus (T1DM): Cell-mediated autoimmune destruction of insulin-producing $\beta$-cells within pancreatic islets of Langerhans. Characterized by circulating autoantibodies: Glutamic Acid Decarboxylase ($GAD_{65}$), Islet Antigen-2 ($IA\text{-}2$), Insulin Autoantibodies ($IAA$), and Zinc Transporter 8 ($ZnT8$). Results in absolute insulin deficiency; patients require lifelong exogenous insulin to survive and prevent ketosis.
• Type 2 Diabetes Mellitus (T2DM): Heterogeneous disorder characterized by progressive insulin resistance in peripheral tissues (skeletal muscle, liver, adipose) combined with progressive $\beta$-cell secretory dysfunction:
  • Muscle: Impaired insulin-stimulated GLUT4 translocation reduces peripheral glucose uptake.
  • Liver: Insulin fails to suppress hepatic gluconeogenesis and glycogenolysis, producing fasting hyperglycemia.
  • Adipose Tissue: Accelerated lipolysis elevates circulating free fatty acids (FFAs), driving hepatic steatosis, muscle lipotoxicity, and worsening insulin resistance.
  • Incretin Defect: Blunted postprandial Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) secretion and action, coupled with unsuppressed postprandial glucagon secretion by pancreatic $\alpha$-cells.
• Diagnostic Criteria (Diabetes Canada):
  • Fasting Plasma Glucose (FPG) $\ge 7.0\text{ mmol/L}$ (fasting $\ge 8\text{ hours}$).
  • Glycated Hemoglobin (HbA1c) $\ge 6.5%$ (standardized NGSP assay).
  • 2-Hour Plasma Glucose (2hPG) $\ge 11.1\text{ mmol/L}$ in a $75\text{ g}$ Oral Glucose Tolerance Test (OGTT).
  • Random Plasma Glucose $\ge 11.1\text{ mmol/L}$ in the presence of classic symptoms (polyuria, polydipsia, unexplained weight loss).

2. Acute Metabolic Emergencies: DKA vs HHS

3. Thyroid and Adrenal Pathophysiology

• Hypothyroidism:
  • Primary (Hashimoto's Thyroiditis): Autoimmune destruction of thyroid follicular cells mediated by anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-Tg) antibodies. Laboratory profile: Elevated TSH, Low Free T4. Features: fatigue, cold intolerance, weight gain, constipation, dry skin, bradycardia, delayed deep tendon reflex relaxation, myxedema.
  • Secondary/Tertiary: Pituitary or hypothalamic failure. Laboratory profile: Low/Normal TSH with Low Free T4.
• Hyperthyroidism / Thyrotoxicosis:
  • Graves' Disease: Autoimmune disorder caused by Thyroid-Stimulating Immunoglobulins (TSI / TRAb) that bind to and activate TSH receptors, stimulating autonomous thyroid hormone synthesis. Laboratory profile: Suppressed/Undetectable TSH ($< 0.01\text{ mIU/L}$), Elevated Free T4 and/or Free T3. Features: heat intolerance, weight loss despite increased appetite, palpitations, fine tremor, hyperreflexia, diffuse vascular goiter with bruit, orbitopathy/exophthalmos, and pretibial myxedema.
  • Thyroid Storm: Life-threatening hypermetabolic crisis triggered by infection, surgery, or radioiodine. Manifests with hyperpyrexia ($> 40^\circ\text{C}$), marked tachycardia/atrial fibrillation, agitation, delirium, jaundice, and high-output heart failure.
• Adrenal Pathophysiology:
  • Primary Adrenal Insufficiency (Addison's Disease): Autoimmune destruction of all three adrenal cortical zones (cortex). Deficiencies in cortisol, aldosterone, and androgens with elevated ACTH. Features: hyperpigmentation (pro-opiomelanocortin/ACTH cleavage to $\alpha$-MSH), orthostatic hypotension, hyponatremia, hyperkalemia, hypoglycemia.
  • Secondary Adrenal Insufficiency: Pituitary ACTH deficiency or abrupt withdrawal of chronic exogenous corticosteroid therapy leading to prolonged hypothalamic-pituitary-adrenal (HPA) axis suppression. Aldosterone secretion is preserved (regulated by RAAS, not ACTH); hyperpigmentation is absent.
  • Hypercortisolemia (Cushing's Syndrome): Excess glucocorticoids from exogenous steroid administration (most common), pituitary ACTH-secreting adenoma (Cushing's disease), or adrenal adenoma. Manifests with central adiposity, moon facies, buffalo hump, purple abdominal striae, proximal muscle wasting, osteoporosis, hypertension, and hyperglycemia.

---

Renal Pathophysiology

+-------------------------------------------------------------------------+
|                    ACUTE KIDNEY INJURY (AKI) TAXONOMY                   |
+-------------------------------------------------------------------------+
|                                                                         |
|  [PRE-RENAL] (Hypoperfusion)             [INTRINSIC] (Structural Damage)|
|  - Volume depletion, HF, Sepsis          - ATN: Ischemic / Nephrotoxic  |
|  - Afferent: NSAIDs (constrict)          - AIN: Drug-allergic (PPI/ABX) |
|  - Efferent: ACEi/ARBs (dilate)          - Glomerulonephritis           |
|  - BUN:Cr > 20:1, FeNa < 1%              - Muddy brown casts, FeNa > 2% |
|                                                                         |
|  [POST-RENAL] (Obstruction) ----------------> BPH, Stones, Neoplasm     |
|                                                                         |
+-------------------------------------------------------------------------+

1. Acute Kidney Injury (AKI): Pre-Renal, Intrinsic, and Post-Renal

KDIGO defines AKI as an increase in serum creatinine by $\ge 26.5,\mu\text{mol/L}$ within 48 hours, a $\ge 1.5$-fold rise above baseline within 7 days, or urine volume $< 0.5\text{ mL/kg/h}$ for 6 hours.

1. Pre-Renal AKI (Hemodynamic/Hypoperfusion):
   • Renal parenchyma remains structurally intact. Decreased effective circulating arterial volume (hypovolemia, congestive heart failure, cirrhosis) lowers renal perfusion pressure below autoregulatory thresholds ($< 80\text{ mmHg}$ MAP).
   • Glomerular Hemodynamics: Autoregulation normally maintains GFR via prostaglandin-mediated afferent arteriolar vasodilation and angiotensin II-mediated efferent arteriolar vasoconstriction.
   • Drug Interference: NSAIDs block vasodilatory prostaglandins (constricting afferent arterioles), while ACE inhibitors / ARBs block angiotensin II (dilating efferent arterioles), precipitously dropping intraglomerular hydrostatic pressure and GFR.
   • Laboratory Profile: $\text{BUN}:\text{SCr} > 20:1$, Fractional Excretion of Sodium ($\text{FeNa}$) $< 1%$, Urine Sodium $< 20\text{ mmol/L}$, high urine osmolality ($> 500\text{ mOsm/kg}$), hyaline casts.
2. Intrinsic / Intrarenal AKI (Structural Parenchymal Damage):
   • Acute Tubular Necrosis (ATN; $\sim 85%$ of intrinsic AKI): Caused by prolonged severe ischemia (untreated pre-renal state) or nephrotoxins (aminoglycosides, iodinated radiocontrast agents, amphotericin B, cisplatin). Sloughing of tubular epithelial cells into lumens causes intratubular obstruction, back-leak of filtrate, and loss of tubular concentrating ability. Laboratory Profile: Muddy brown granular casts, $\text{FeNa} > 2%$, Urine Sodium $> 40\text{ mmol/L}$, low urine osmolality ($< 350\text{ mOsm/kg}$).
   • Acute Interstitial Nephritis (AIN): Type IV cell-mediated hypersensitivity reaction within the renal interstitium induced by drugs (beta-lactams, ciprofloxacin, sulfonamides, proton pump inhibitors, NSAIDs). Classical triad (seen in $< 30%$): low-grade fever, maculopapular rash, peripheral eosinophilia; urinalysis shows WBC casts, pyuria, and eosinophiluria.
   • Acute Glomerulonephritis: Immune complex deposition causing glomerular basement membrane inflammation, hematuria, proteinuria, and dysmorphic RBC casts.
3. Post-Renal AKI (Urinary Tract Obstruction):
   • Mechanical obstruction to urinary outflow at the ureteral, bladder neck, or urethral level (benign prostatic hyperplasia [BPH], nephrolithiasis, pelvic tumors, neurogenic bladder, or anticholinergic medication toxicity).
   • Increased retrograde hydrostatic pressure within Bowman's capsule opposes glomerular filtration, reducing net GFR.

2. Chronic Kidney Disease and Mineral-Bone Disorder (CKD-MBD)

CKD is defined as persistent abnormalities of kidney structure or function (eGFR $< 60\text{ mL/min}/1.73,\text{m}^2$ or urinary albumin-to-creatinine ratio [ACR] $\ge 3.0\text{ mg/mmol}$) for $\ge 3\text{ months}$.

+-------------------------------------------------------------------------+
|                    PATHOGENESIS OF CKD-MBD CASCADE                      |
+-------------------------------------------------------------------------+
|                                                                         |
|  1. Nephron Loss -> Decreased GFR -> Renal Phosphate Retention          |
|                                |                                        |
|                                v                                        |
|  2. Elevated Serum Phosphate & Increased FGF-23 Secretion               |
|                                |                                        |
|                                v                                        |
|  3. Downregulation of Renal 1-alpha-hydroxylase (CYP27B1)               |
|                                |                                        |
|                                v                                        |
|  4. Impaired Synthesis of Active Calcitriol [1,25-(OH)2-Vitamin D3]     |
|                                |                                        |
|                                v                                        |
|  5. Reduced Intestinal Calcium Absorption -> True Hypocalcemia          |
|                                |                                        |
|                                v                                        |
|  6. Parathyroid Chief Cell Stimulation -> Secondary Hyperparathyroidism |
|                                |                                        |
|                                v                                        |
|  7. Excessive PTH -> High Bone Turnover, Osteodystrophy, Calcification  |
|                                                                         |
+-------------------------------------------------------------------------+

• CKD-MBD Mechanism:
  1. As functional nephron mass declines, renal clearance of phosphate decreases, leading to hyperphosphatemia.
  2. Elevated phosphate stimulates osteocytes to secrete Fibroblast Growth Factor 23 (FGF-23).
  3. Elevated FGF-23 and damaged renal parenchyma downregulate renal $1\alpha$-hydroxylase (CYP27B1), severely blunting the conversion of 25-hydroxyvitamin D into active calcitriol (1,25-dihydroxyvitamin D).
  4. Diminished calcitriol reduces active intestinal absorption of calcium, producing hypocalcemia.
  5. Hyperphosphatemia, hypocalcemia, and calcitriol deficiency stimulate parathyroid gland chief cells to produce excessive Parathyroid Hormone (PTH), resulting in Secondary Hyperparathyroidism.
  6. Chronically elevated PTH mobilizes calcium and phosphorus from skeletal reserves (renal osteodystrophy, osteitis fibrosa cystica) and promotes metastatic vascular and soft-tissue calcification (accelerating cardiovascular mortality).

---

Gastrointestinal and Hepatic Pathophysiology

1. Peptic Ulcer Disease (PUD) and GERD

• Gastroesophageal Reflux Disease (GERD): Driven by transient lower esophageal sphincter relaxations (TLESRs), hypotensive basal LES resting tone, hiatal hernia, delayed gastric emptying, and impaired esophageal acid clearance. Acid, pepsin, and bile contact esophageal squamous epithelium, causing inflammation, erosion, and potential metaplasia to specialized columnar epithelium (Barrett's Esophagus, a premalignant lesion for esophageal adenocarcinoma).
• Peptic Ulcer Disease (PUD): Mucosal break $\ge 5\text{ mm}$ in diameter extending through the muscularis mucosae.
  • Helicobacter pylori Infection: Microaerophilic, Gram-negative bacterium producing bacterial urease (converts urea into ammonia and $\text{CO}_2$, buffering gastric acid to permit bacterial colonization). Induces chronic active gastritis, secretes cytotoxins (CagA, VacA), breaks down protective mucosal mucus barriers, and increases gastrin secretion.
  • NSAID-Induced Mucosal Injury: Systemic non-selective inhibition of Cyclooxygenase-1 (COX-1) depletes mucosal cytoprotective prostaglandins ($\text{PGE}_2, \text{PGI}_2$). This suppresses bicarbonate secretion, reduces mucosal blood flow, impairs mucus synthesis, and diminishes epithelial cell turnover.

2. Inflammatory Bowel Disease (IBD): Crohn's vs Ulcerative Colitis

3. Hepatic Cirrhosis, Portal Hypertension, and ESLD Complications

Cirrhosis is the histopathological end-stage of chronic liver injury (viral hepatitis, alcohol, metabolic dysfunction-associated steatohepatitis [MASH]), characterized by diffuse hepatic fibrosis, replacement of normal architecture by regenerative parenchymal nodules, and vascular distortion.

+-------------------------------------------------------------------------+
|                 PORTAL HYPERTENSION & CIRRHOSIS SEQUELAE                |
+-------------------------------------------------------------------------+
|                                                                         |
|  Hepatic Fibrosis -> Increased Intrahepatic Resistance -> Portal HTN    |
|       |                                                                 |
|       |-- Splanchnic Vasodilation -> Hypovolemia -> RAAS -> [ASCITES]   |
|       |                                                                 |
|       |-- Portosystemic Collaterals -> Gastroesophageal [VARICES]       |
|       |                                                                 |
|       |-- Shunting & Hepatocyte Loss -> Ammonia -> [ENCEPHALOPATHY]     |
|       |                                                                 |
|       +-- Spleen Congestion -> Hypersplenism -> [THROMBOCYTOPENIA]      |
|                                                                         |
+-------------------------------------------------------------------------+

• Portal Hypertension (HVPG $> 5\text{ mmHg}$; clinically significant $\ge 10\text{ mmHg}$): Fibrotic sinusoids and perisinusoidal stellate cell activation increase hepatic vascular resistance. Excessive nitric oxide production in the splanchnic circulation induces massive splanchnic vasodilation and hyperdynamic circulation.
• Ascites: Splanchnic arterial vasodilation decreases effective arterial blood volume, triggering intense compensatory activation of the RAAS, sympathetic nervous system, and ADH. The resulting profound renal sodium and water retention, coupled with sinusoidal hypertension and hypoalbuminemia (reduced plasma oncotic pressure), drives transudation of fluid into the peritoneal cavity.
• Spontaneous Bacterial Peritonitis (SBP): Spontaneous infection of ascitic fluid without an intra-abdominal surgically treatable source. Diagnosed when ascitic fluid paracentesis reveals an absolute neutrophil count (ANC) $\ge 250 \times 10^6/\text{L}$ ($\ge 0.25 \times 10^9/\text{L}$).
• Gastroesophageal Varices: Portal hypertension diverts portal blood flow into low-pressure portosystemic collateral vessels (esophagogastric junction, hemorrhoidal plexus, caput medusae). Varices dilate and rupture when wall tension exceeds tensile strength, causing life-threatening upper gastrointestinal hemorrhage.
• Hepatic Encephalopathy (HE): Impaired hepatic parenchymal clearance and direct portosystemic shunting allow gut-derived neurotoxins (principally ammonia, generated by intestinal bacteria from dietary protein) to cross the blood-brain barrier. Ammonia is metabolized by astrocytes into glutamine, causing astrocyte swelling, cerebral edema, neurotransmitter imbalance (GABAergic upregulation), and clinical manifestations ranging from inverted sleep patterns to asterixis (flapping tremor) and coma.